ALX ONCOLOGY HOLDINGS INC Finance Lease, Right-of-Use Asset, Amortization
ALX ONCOLOGY HOLDINGS INC (ALXO) reported Finance Lease, Right-of-Use Asset, Amortization of $239.00 thousand for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:FinanceLeaseRightOfUseAssetAmortization · last filed 2026-08-06
- ALX ONCOLOGY HOLDINGS INC finance lease, right-of-use asset, amortization for the quarter ending 2026-06-30 was $239.00K, a 8.43% decline year-over-year.
- ALX ONCOLOGY HOLDINGS INC finance lease, right-of-use asset, amortization for the quarter ending 2026-03-31 was $239.00K, a 8.78% decline year-over-year.
- ALX ONCOLOGY HOLDINGS INC finance lease, right-of-use asset, amortization for the quarter ending 2025-12-31 was $239.00K, a 8.78% decline year-over-year.
- ALX ONCOLOGY HOLDINGS INC finance lease, right-of-use asset, amortization for the quarter ending 2025-09-30 was $247.00K, a 2.76% decline year-over-year.
- ALX ONCOLOGY HOLDINGS INC finance lease, right-of-use asset, amortization for fiscal 2025 was $1.01M, a 4.89% increase from fiscal 2024.
- ALX ONCOLOGY HOLDINGS INC finance lease, right-of-use asset, amortization for fiscal 2024 was $962.00K, a 95.13% increase from fiscal 2023.
- ALX ONCOLOGY HOLDINGS INC finance lease, right-of-use asset, amortization for fiscal 2023 was $493.00K, a 10.29% increase from fiscal 2022.
- ALX ONCOLOGY HOLDINGS INC finance lease, right-of-use asset, amortization for fiscal 2022 was $447.00K, a 21.14% increase from fiscal 2021.
| Period end | Finance Lease, Right-of-Use Asset, Amortization 3 month | Finance Lease, Right-of-Use Asset, Amortization 6 month | Finance Lease, Right-of-Use Asset, Amortization 9 month | Finance Lease, Right-of-Use Asset, Amortization 12 month |
|---|---|---|---|---|
| 2026-06-30 | $239.00K 10-Q · filed 2026-08-06 | $478.00K 10-Q · filed 2026-08-06 | $717.00K derived: sum of 3 quarters · filed 2026-08-06 | $964.00K derived: sum of 4 quarters · filed 2026-08-06 |
| 2026-03-31 | $239.00K 10-Q · filed 2026-05-08 | $478.00K derived: sum of 2 quarters · filed 2026-05-08 | $725.00K derived: sum of 3 quarters · filed 2026-05-08 | $986.00K derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-12-31 | $239.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-09 | $486.00K derived: sum of 2 quarters · filed 2026-03-09 | $747.00K derived: sum of 3 quarters · filed 2026-08-06 | $1.01M 10-K · filed 2026-03-09 |
| 2025-09-30 | $247.00K 10-Q · filed 2025-11-07 | $508.00K derived: sum of 2 quarters · filed 2026-08-06 | $770.00K 10-Q · filed 2025-11-07 | $1.03M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-06-30 | $261.00K 10-Q · filed 2026-08-06 | $523.00K 10-Q · filed 2026-08-06 | $785.00K derived: sum of 3 quarters · filed 2026-08-06 | $1.04M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-03-31 | $262.00K 10-Q · filed 2026-05-08 | $524.00K derived: sum of 2 quarters · filed 2026-05-08 | $778.00K derived: sum of 3 quarters · filed 2026-05-08 | $975.00K derived: sum of 4 quarters · filed 2026-05-08 |
| 2024-12-31 | $262.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-09 | $516.00K derived: sum of 2 quarters · filed 2026-03-09 | $713.00K derived: sum of 3 quarters · filed 2026-03-09 | $962.00K 10-K · filed 2026-03-09 |
| 2024-09-30 | $254.00K 10-Q · filed 2025-11-07 | $451.00K derived: sum of 2 quarters · filed 2025-11-07 | $700.00K 10-Q · filed 2025-11-07 | $855.00K derived: sum of 4 quarters · filed 2026-03-09 |
| 2024-06-30 | $197.00K 10-Q · filed 2025-08-12 | $446.00K 10-Q · filed 2025-08-12 | $601.00K derived: sum of 3 quarters · filed 2026-03-09 | $715.00K derived: sum of 4 quarters · filed 2026-03-09 |
| 2024-03-31 | $249.00K 10-Q · filed 2025-05-08 | $404.00K derived: sum of 2 quarters · filed 2026-03-09 | $518.00K derived: sum of 3 quarters · filed 2026-03-09 | $630.00K derived: sum of 4 quarters · filed 2026-03-09 |
| 2023-12-31 | $155.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-09 | $269.00K derived: sum of 2 quarters · filed 2026-03-09 | $381.00K derived: sum of 3 quarters · filed 2026-03-09 | $493.00K 10-K · filed 2026-03-09 |
| 2023-09-30 | $114.00K 10-Q · filed 2024-11-07 | $226.00K derived: sum of 2 quarters · filed 2024-11-07 | $338.00K 10-Q · filed 2024-11-07 | $449.00K derived: sum of 4 quarters · filed 2025-03-06 |
| 2023-06-30 | $112.00K 10-Q · filed 2023-08-10 | $224.00K 10-Q · filed 2024-08-12 | $335.00K derived: sum of 3 quarters · filed 2025-03-06 | $447.00K derived: sum of 4 quarters · filed 2025-03-06 |
| 2023-03-31 | $112.00K 10-Q · filed 2024-08-12 | $223.00K derived: sum of 2 quarters · filed 2025-03-06 | $335.00K derived: sum of 3 quarters · filed 2025-03-06 | $447.00K derived: sum of 4 quarters · filed 2025-03-06 |
| 2022-12-31 | $111.00K derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-06 | $223.00K derived: sum of 2 quarters · filed 2025-03-06 | $335.00K derived: sum of 3 quarters · filed 2025-03-06 | $447.00K 10-K · filed 2025-03-06 |
| 2022-09-30 | $112.00K 10-Q · filed 2023-11-13 | $224.00K derived: sum of 2 quarters · filed 2023-11-13 | $336.00K 10-Q · filed 2023-11-13 | $448.00K derived: sum of 4 quarters · filed 2024-03-07 |
| 2022-06-30 | $112.00K 10-Q · filed 2023-08-10 | $224.00K 10-Q · filed 2023-08-10 | $336.00K derived: sum of 3 quarters · filed 2024-03-07 | $448.00K derived: sum of 4 quarters · filed 2024-03-07 |
| 2022-03-31 | $112.00K 10-Q · filed 2023-05-11 | $224.00K derived: sum of 2 quarters · filed 2024-03-07 | $336.00K derived: sum of 3 quarters · filed 2024-03-07 | $426.00K derived: sum of 4 quarters · filed 2024-03-07 |
| 2021-12-31 | $112.00K derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-07 | $224.00K derived: sum of 2 quarters · filed 2024-03-07 | $314.00K derived: sum of 3 quarters · filed 2024-03-07 | $369.00K 10-K · filed 2024-03-07 |
| 2021-09-30 | $112.00K 10-Q · filed 2022-11-08 | $202.00K derived: sum of 2 quarters · filed 2022-11-08 | $257.00K 10-Q · filed 2022-11-08 | |
| 2021-06-30 | $90.00K 10-Q · filed 2022-08-08 | $145.00K 10-Q · filed 2022-08-08 | ||
| 2021-03-31 | $23.00K 10-Q · filed 2022-05-09 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Fortress Biotech, Inc. (FBIO) | United States | $0.188B | 0.91 |
| PepGen Inc. (PEPG) | United States | $0.186B | -1.73 |
| AN2 Therapeutics, Inc. (ANTX) | United States | $0.185B | -4.84 |
| Organogenesis Holdings Inc. (ORGO) | United States | $0.182B | -3.70 |
| Zentalis Pharmaceuticals, Inc. (ZNTL) | United States | $0.196B | -2.48 |
| ORAMED PHARMACEUTICALS INC. (ORMP) | $0.199B | 1.13 | |
| Nkarta, Inc. (NKTX) | United States | $0.205B | -1.73 |
| Tonix Pharmaceuticals Holding Corp. (TNXP) | United States | $0.166B | -1.34 |
| Minerva Neurosciences, Inc. (NERV) | United States | $0.165B | -0.66 |
| ADC Therapeutics SA (ADCT) | $0.163B | -1.39 |